"Intravitreal Injections" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The administration of substances into the VITREOUS BODY of the eye with a hypodermic syringe.
| Descriptor ID |
D058449
|
| MeSH Number(s) |
E02.319.267.530.475.500
|
| Concept/Terms |
Intravitreal Injections- Intravitreal Injections
- Injection, Intravitreal
- Injections, Intravitreal
- Intravitreal Injection
|
Below are MeSH descriptors whose meaning is more general than "Intravitreal Injections".
Below are MeSH descriptors whose meaning is more specific than "Intravitreal Injections".
This graph shows the total number of publications written about "Intravitreal Injections" by people in this website by year, and whether "Intravitreal Injections" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 3 | 0 | 3 |
| 2013 | 0 | 2 | 2 |
| 2014 | 2 | 1 | 3 |
| 2015 | 0 | 4 | 4 |
| 2016 | 0 | 8 | 8 |
| 2017 | 0 | 3 | 3 |
| 2021 | 0 | 3 | 3 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 3 | 3 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Intravitreal Injections" by people in Profiles.
-
Danzig CJ, Khanani AM, Kaiser PK, Chang MA, Kovach JL, Lally DR, Rachitskaya A, Sheth VS, Vajzovic L, Clark J, Tang J, Zhu L, Desai D, Chakravarthy U. Vision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy: A 12-Month Post Hoc Analysis of the GATHER1 and GATHER2 Trials. Ophthalmol Retina. 2024 Nov; 8(11):1052-1060.
-
Lam A, Gulati S, Foster BS, Lally DR. CENTRAL RETINAL VEIN OCCLUSION ASSOCIATED WITH USE OF AMYL NITRITE "POPPERS". Retin Cases Brief Rep. 2024 Jan 01; 18(1):138-140.
-
Archambault SD, Nichols MM, McCullum JC, Zhang Y, Steinberger EE, Ramsey DJ. Patient adherence to therapy after switch to aflibercept from bevacizumab or ranibizumab for treatment-refractory neovascular age-related macular degeneration. Indian J Ophthalmol. 2024 Jan 01; 72(Suppl 1):S101-S105.
-
Akkan Aydogmus FS, Onwuka O, Saddemi J, Lasalle CC, Ramsey DJ. Second eyes to develop neovascular age-related macular degeneration have fewer symptoms and better one-year visual outcomes. BMC Ophthalmol. 2023 Jul 07; 23(1):303.
-
Patel SS, Lally DR, Hsu J, Wykoff CC, Eichenbaum D, Heier JS, Jaffe GJ, Westby K, Desai D, Zhu L, Khanani AM. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial. Eye (Lond). 2023 12; 37(17):3551-3557.
-
Lally DR, Loewenstein A, Arnold JJ, Yang YC, Gedif K, Best C, Patel H, Tadayoni R, Heier JS. Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies. Eye (Lond). 2023 04; 37(6):1242-1248.
-
Foster WJ, Berg BW, Luminais SN, Hadayer A, Schaal S. Computational Modeling of Ophthalmic Procedures: Computational Modeling of Ophthalmic Procedures. Am J Ophthalmol. 2022 09; 241:87-107.
-
Ramsey DJ, McCullum JC, Steinberger EE, Zhang Y, Alwreikat AM, Cooper ML, Roh S, Cotran PR. Intraocular pressure decreases in eyes with glaucoma-related diagnoses after conversion to aflibercept for treatment-resistant age-related macular degeneration. Eye (Lond). 2022 09; 36(9):1813-1819.
-
Sahu B, Chug I, Khanna H. The Ocular Gene Delivery Landscape. Biomolecules. 2021 08 01; 11(8).
-
Cheng SY, Luo Y, Malachi A, Ko J, Su Q, Xie J, Tian B, Lin H, Ke X, Zheng Q, Tai PWL, Gao G, Punzo C. Low-Dose Recombinant Adeno-Associated Virus-Mediated Inhibition of Vascular Endothelial Growth Factor Can Treat Neovascular Pathologies Without Inducing Retinal Vasculitis. Hum Gene Ther. 2021 07; 32(13-14):649-666.